PHOTOCURE ASA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.5 NOK | -2.87% |
|
-4.49% | -14.69% |
| May. 15 | Transcript : Photocure ASA, Q1 2024 Earnings Call, May 15, 2024 | |
| May. 15 | Photocure ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 498M 46.56M | Sales 2025 * | 595M 55.72M | Capitalization | 1.6B 150M |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 | Net income 2025 * | 51M 4.77M | EV / Sales 2024 * | 2.65 x |
| Net cash position 2024 * | 284M 26.58M | Net cash position 2025 * | 336M 31.45M | EV / Sales 2025 * | 2.13 x |
| P/E ratio 2024 * |
-2,843
x | P/E ratio 2025 * |
31.3
x | Employees | 102 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.3% |
More Fundamentals
* Assessed data
More news
Latest transcript on Photocure ASA
More press releases
| 1 day | -2.87% | ||
| 1 week | -4.49% | ||
| Current month | +3.98% | ||
| 1 month | +5.70% | ||
| 3 months | +3.42% | ||
| 6 months | +16.28% | ||
| Current year | -14.69% |
1 week
57.50
61.90
1 month
52.3063.10
Current year
52.0071.90
1 year
40.7071.90
3 years
40.70154.50
5 years
40.00154.50
10 years
17.70154.50
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Schneider
CEO | Chief Executive Officer | - | 18-10-31 |
Erik Dahl
DFI | Director of Finance/CFO | - | 12-08-14 |
Anders Neijber
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Johanna Holldack
BRD | Director/Board Member | - | 17-04-27 |
Malene Brondberg
BRD | Director/Board Member | 51 | - |
Dylan Hallerberg
CHM | Chairman | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 57.5 | -2.87% | 149 573 |
| 24-05-21 | 59.2 | -1.33% | 109,661 |
| 24-05-16 | 60 | -0.33% | 64,731 |
| 24-05-15 | 60.2 | -4.14% | 114,337 |
| 24-05-14 | 62.8 | +3.80% | 141,977 |
Real-time Oslo Bors, May 22, 2024 at 07:30 am EDT
More quotes
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Companyâs activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Sector
Pharmaceuticals
Calendar
2024-05-23
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
59.2
NOK
Average target price
86
NOK
Spread / Average Target
+45.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.69% | 150M | |
| +37.78% | 723B | |
| +31.17% | 598B | |
| -3.51% | 364B | |
| +19.94% | 331B | |
| +5.14% | 288B | |
| +16.21% | 244B | |
| -4.83% | 208B | |
| +9.97% | 210B | |
| +9.32% | 169B |
- Stock Market
- Equities
- PHO Stock
